248 related articles for article (PubMed ID: 3943086)
1. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.
Desgranges C; Razaka G; De Clercq E; Herdewijn P; Balzarini J; Drouillet F; Bricaud H
Cancer Res; 1986 Mar; 46(3):1094-101. PubMed ID: 3943086
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
Naguib FN; Hao SN; el Kouni MH
Cancer Res; 1994 Oct; 54(19):5166-70. PubMed ID: 7923135
[TBL] [Abstract][Full Text] [Related]
3. Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation.
Sommadossi JP; Gewirtz DA; Cross DS; Goldman ID; Cano JP; Diasio RB
Cancer Res; 1985 Jan; 45(1):116-21. PubMed ID: 3965128
[TBL] [Abstract][Full Text] [Related]
4. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.
Tuchman M; Ramnaraine ML; O'Dea RF
Cancer Res; 1985 Nov; 45(11 Pt 1):5553-6. PubMed ID: 4053028
[TBL] [Abstract][Full Text] [Related]
5. [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy].
Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):760-8. PubMed ID: 6424581
[TBL] [Abstract][Full Text] [Related]
6. Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys.
Holstege A; Pausch J; Gerok W
Cancer Res; 1986 Nov; 46(11):5576-81. PubMed ID: 3756903
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear pharmacokinetics of thymidine, thymine, and fluorouracil and their kinetic interactions in normal dogs.
Covey JM; Straw JA
Cancer Res; 1983 Oct; 43(10):4587-95. PubMed ID: 6883317
[TBL] [Abstract][Full Text] [Related]
8. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
9. In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides.
Santelli G; Valeriote F
J Natl Cancer Inst; 1980 Jan; 64(1):69-72. PubMed ID: 6928048
[TBL] [Abstract][Full Text] [Related]
10. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
11. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
[TBL] [Abstract][Full Text] [Related]
12. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi K; Watabe T; Ogura Y
Drug Metab Dispos; 1997 Feb; 25(2):270-3. PubMed ID: 9029059
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral injection of thymidine: enhancement of the antitumor activity and incorporation of 5-fluorouracil into tumor RNA in a murine tumor system.
Matsuoka H; Masuda H; Maehara Y; Sugimachi K; Inokuchi K
Cancer Treat Rep; 1986 Jul; 70(7):851-7. PubMed ID: 3719577
[TBL] [Abstract][Full Text] [Related]
14. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.
Kanamitsu SI; Ito K; Okuda H; Ogura K; Watabe T; Muro K; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):467-74. PubMed ID: 10725316
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.
Tatsumi K; Fukushima M; Shirasaka T; Fujii S
Jpn J Cancer Res; 1987 Jul; 78(7):748-55. PubMed ID: 3114201
[TBL] [Abstract][Full Text] [Related]
16. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate.
Ho DH; Townsend L; Luna MA; Bodey GP
Anticancer Res; 1986; 6(4):781-4. PubMed ID: 3752956
[TBL] [Abstract][Full Text] [Related]
17. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Ogura K; Kato A; Takubo H; Watabe T
J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
[TBL] [Abstract][Full Text] [Related]
18. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
19. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
Cao S; Frank C; Shirasaka T; Rustum YM
Clin Cancer Res; 1995 Aug; 1(8):839-45. PubMed ID: 9816053
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of the bitter melon (Momordica charantia).
Jilka C; Strifler B; Fortner GW; Hays EF; Takemoto DJ
Cancer Res; 1983 Nov; 43(11):5151-5. PubMed ID: 6616452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
